Occurrence of acute monocytic leukemia in a case of untreated Waldenström's macroglobulinemia

Murashige, Naoko; Tabanda, Rosa; Zalusky, Ralph

doi:10.1002/ajh.10167

Cited by 3 publications

(4 citation statements)

References 14 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with AML who receive intensive chemotherapy may achieve complete remission; however, the overall survival rate of patients with AML is poor and the treatment is typically associated with serious complications (4). In addition, there is no optimal therapeutic schedule for each type of AMoL (5). Therefore, the aim of the present study was to identify a novel drug for treating M 5 (AMoL).…”

Section: Introductionmentioning

confidence: 98%

“…The principal therapeutic strategies for patients with AML are aggressive chemotherapeutic regimens and hematopoietic stem cell transplantation (HSCT) (1)(2)(3). However, AML consists of 8 subtypes, including M 0 (minimally differentiated AML), M 1 (AML without maturation), M 2 (AML with maturation), M 3 (acute promyelocytic leukemia), M 4 (acute myelomonocytic leukemia), M 5 [acute monocytic leukemia (AMoL)], M 6 (erythroleukemia) and M 7 (acute megakaryoblastic leukemia). Patients with AML who receive intensive chemotherapy may achieve complete remission; however, the overall survival rate of patients with AML is poor and the treatment is typically associated with serious complications (4).…”

Section: Introductionmentioning

confidence: 99%

“…Furthermore, the clinical complete remission rate is low with poor prognosis. A total of 87 different translocations have been identified, with 11q23 chromosomal abnormalities accounting for ~22% of M 5 cases. There are various chemotherapy regimens used to treat patients with AMoL including: i) Homoharringtonine, cytarabine and etoposide; ii) daunorubicin, Ara-c and teniposide; and iii) mitoxantrone, Ara-c and teniposide (7).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Dihydroartemisinin-induced apoptosis in human acute monocytic leukemia cells

Cao

Wang

et al. 2017

Oncol Lett

View full text Add to dashboard Cite

Abstract. Dihydroartemisinin (DHA) is a derivative of artemisinin. The present study aimed to investigate whether DHA induces apoptosis in the THP-1 human acute monocytic leukemia cell line (AMoL), and to identify the relative molecular mechanisms. The results of the present study demonstrated that the viability of THP-1 cells were inhibited by DHA in a dose-and time-dependent manner, which was accompanied by morphological characteristics associated with apoptosis. After 24 h of 200 µM DHA treatment, the proportion of apoptotic cells was significantly increased compared with the untreated controls (P<0.01). In addition, DHA downregulated the levels of B-cell lymphoma (Bcl)-2, protein kinase B (Akt)1, Akt2 and Akt3 gene expression, and increased the expression of the Bcl-2-associated X protein apoptosis regulator. The protein expression of phospho-Akt and phospho-extracellular signal-regulated kinase (ERK) was also decreased, and the protein expression level of cleaved caspase-3 was increased following treatment with DHA. Therefore, DHA may induce apoptosis in the AMoL THP-1 cell line via currently unknown underlying molecular mechanisms, including the downregulation of ERK and Akt, and the activation of caspase-3.

show abstract

Section: Introductionmentioning

confidence: 98%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Dihydroartemisinin-induced apoptosis in human acute monocytic leukemia cells

Cao

Wang

et al. 2017

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…The occurrence of therapy-related AML as a late complication of cytotoxic therapy is well documented [1], and several regimens for the treatment of plasma cell myeloma (PCM) have been associated with the development of myeloid neoplasms, such as AML, myelodysplastic syndrome, and myeloproliferative neoplasm [2]. The simultaneous occurrence of AML with various plasma cell dyscrasias without prior exposure to chemotherapy or radiotherapy is extremely rare, and most reported cases are of the myelomonocytic or monocytic subtype [3-6]. …”

mentioning

confidence: 99%

A Case of Acute Promyelocytic Leukemia Concomitant with Plasma Cell Myeloma

et al. 2014

View full text Add to dashboard Cite

Simultaneous presentation of acute monoblastic leukemia and mantle cell lymphoma: Case report and review of the literature

Pawarode

Baer

Padmanabhan

et al. 2005

Leukemia & Lymphoma

View full text Add to dashboard Cite

This paper reports a 73-year old woman with simultaneous presentation of acute monoblastic leukemia (acute myeloid leukemia (AML), French-American-British (FAB) type M5a) and mantle cell lymphoma. The patient presented with wasting, generalized lymphadenopathy, an extensive infiltrative rash and pancytopenia. Bone marrow and lymph node histopatholology showed extensive infiltration by leukemic monoblasts. Marrow cytogenetics revealed a complex karyotype, including t(8;16)(p11;p13). Flow cytometric immunophenotyping of peripheral blood, lymph node and bone marrow demonstrated two populations, expressing CD5, CD19, CD20 and CD22 and CD45, HLA-DR, CD13, CD33, CD14 and CD38, respectively. A focus of abnormal lymphocytes in the lymph node biopsy demonstrated BCL1 expression and t(11;14)(p11;p13) by fluorescence in situ hybridization and immunoglobulin heavy chain gene rearrangement by the polymerase chain reaction. The patient received infusional cytarabine, daunorubicin and etoposide chemotherapy, with complete remission of both the AML and the mantle cell leukemia. To the authors' knowledge, this is the first report of simultaneous presentations of AML, FAB M5a and mantle cell lymphoma. The case is discussed and the literature is reviewed.

show abstract

Occurrence of acute monocytic leukemia in a case of untreated Waldenström's macroglobulinemia

Cited by 3 publications

References 14 publications

Dihydroartemisinin-induced apoptosis in human acute monocytic leukemia cells

Dihydroartemisinin-induced apoptosis in human acute monocytic leukemia cells

A Case of Acute Promyelocytic Leukemia Concomitant with Plasma Cell Myeloma

Simultaneous presentation of acute monoblastic leukemia and mantle cell lymphoma: Case report and review of the literature

Contact Info

Product

Resources

About